CTOs on the Move

ST CATHRINE REGINAL HOSP

www.stchc.com

 
ST CATHRINE REGINAL HOSP is a Charlestown, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.stchc.com
  • 2200 Market St
    Charlestown, IN USA 47111
  • Phone: 812.256.3301

Executives

Name Title Contact Details

Similar Companies

Agrios Global Holdings

Agrios Global Holdings Ltd. operates as a holding company. The Company, through its subsidiaries, provides aeroponic equipment rental, nutrient procurement, monitoring, and agronomy consultancy services. Agrios Global Holdings serves customers in Canada.

Hysitron

Hysitron is a Eden Prairie, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

BioVectra

BioVectra Inc. is a Charlottetown, PE-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Dicerna

Dicerna is working to improve the lives of people suffering from rare diseases, chronic liver diseases, cardiovascular disease, and viral liver infectious diseases. We discover and develop innovative therapies to stop or turn off destructive disease processes by silencing the genes underlying these processes. Our proprietary, next-generation technology, GalXC™, is a platform that uses the body`s natural biological pathways to silence genes in the liver with a high degree of selectivity and specificity. By targeting genes that contribute to serious diseases, we seek to address the underlying cause of illness and restore health. We have qualified dozens of disease-associated genes in clinical indications where we believe an RNAi-based inhibitor may provide substantial benefit to patients, providing expansive therapeutic opportunities. Dicerna is advancing a growing pipeline of product candidates based on our GalXC platform to deliver transformative therapies to patients. Dicerna brings together talented experts in biology, chemistry, clinical science and medicine. With decades of scientific and technical experience focused on RNAi technology, our team has the knowledge and experience needed to discover, develop and commercialize safe and effective therapies for patients with serious unmet medical needs. Our purpose is clear: delivering life-changing therapies as efficiently as possible to meet the urgent needs of people living with debilitating genetic diseases.